323 related articles for article (PubMed ID: 30507436)
1. Consensus on molecular imaging and theranostics in prostate cancer.
Fanti S; Minozzi S; Antoch G; Banks I; Briganti A; Carrio I; Chiti A; Clarke N; Eiber M; De Bono J; Fizazi K; Gillessen S; Gledhill S; Haberkorn U; Herrmann K; Hicks RJ; Lecouvet F; Montironi R; Ost P; O'Sullivan JM; Padhani AR; Schalken JA; Scher HI; Tombal B; van Moorselaar RJA; Van Poppel H; Vargas HA; Walz J; Weber WA; Wester HJ; Oyen WJG
Lancet Oncol; 2018 Dec; 19(12):e696-e708. PubMed ID: 30507436
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
5. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.
Scheltema MJ; Tay KJ; Postema AW; de Bruin DM; Feller J; Futterer JJ; George AK; Gupta RT; Kahmann F; Kastner C; Laguna MP; Natarajan S; Rais-Bahrami S; Rastinehad AR; de Reijke TM; Salomon G; Stone N; van Velthoven R; Villani R; Villers A; Walz J; Polascik TJ; de la Rosette JJMCH
World J Urol; 2017 May; 35(5):695-701. PubMed ID: 27637908
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
7. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
Kilcoyne A; Harisinghani MG; Mahmood U
J Nucl Med; 2016 Oct; 57(Suppl 3):105S-110S. PubMed ID: 27694162
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
10. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
11. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.
Sumanasuriya S; Omlin A; Armstrong A; Attard G; Chi KN; Bevan CL; Shibakawa A; IJzerman MJ; De Laere B; Lolkema M; Lorente D; Luo J; Mehra N; Olmos D; Scher H; Soule H; Stoecklein NH; Terstappen LWMM; Waugh D; de Bono JS
Eur Urol Oncol; 2018 Jun; 1(2):151-159. PubMed ID: 31100240
[TBL] [Abstract][Full Text] [Related]
12. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
Shakespeare TP
Radiat Oncol; 2015 Nov; 10():233. PubMed ID: 26582424
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in theranostics and challenges for the future.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20170893. PubMed ID: 29565650
[TBL] [Abstract][Full Text] [Related]
14. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
15. Molecular Imaging and Theranostics-A Multidisciplinary Approach.
Farolfi A; Lima GM; Oyen W; Fanti S
Semin Nucl Med; 2019 Jul; 49(4):247-254. PubMed ID: 31227048
[TBL] [Abstract][Full Text] [Related]
16. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
17. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
Padhani AR; Weinreb J; Rosenkrantz AB; Villeirs G; Turkbey B; Barentsz J
Eur Urol; 2019 Mar; 75(3):385-396. PubMed ID: 29908876
[TBL] [Abstract][Full Text] [Related]
18. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
19. Improving Diagnosis of Primary Prostate Cancer With Combined
Jena A; Taneja R; Taneja S; Singh A; Kumar V; Agarwal A; Subramanian N
AJR Am J Roentgenol; 2018 Dec; 211(6):1246-1253. PubMed ID: 30300002
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]